Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Open access

Abstract

The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established. We conducted a phase 2 trial to evaluate the efficacy of pertuzumab plus trastuzumab for metastatic colorectal cancer (mCRC), with human epidermal growth factor receptor 2 ( HER2 ) amplification prospectively confirmed by tumor tissue or ctDNA analysis ( UMIN000027887 ). HER2 amplification was confirmed in tissue and/or ctDNA in 30 patients with mCRC. The study met the primary endpoint with a confirmed objective response rate of 30% in 27 tissue-positive patients and 28% in 25 ctDNA-positive patients, as compared to an objective response rate of 0% in a matched real-world reference population treated with standard-of-care salvage therapy. Post hoc exploratory analyses revealed that baseline ctDNA genotyping of HER2 copy number and concurrent oncogenic alterations adjusted for tumor fraction stratified patients according to efficacy with similar accuracy to tissue genotyping. Decreased ctDNA fraction 3 weeks after treatment initiation associated with therapeutic response. Pertuzumab plus trastuzumab showed similar efficacy in patients with mCRC with HER2 amplification in tissue or ctDNA, showing that ctDNA genotyping can identify patients who benefit from dual-HER2 blockade as well as monitor treatment response. These findings warrant further use of ctDNA genotyping in clinical trials for HER2- amplified mCRC, which might especially benefit patients in first-line treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01553-w

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Clinical efficacy of pertuzumab plus trastuzumab for HER2-amplified mCRC. a, pCN of the ten most frequent gene amplifications in 1,107 patients with mCRC enrolled in GOZILA between January 2018 and March 2020. The pCN of HER2 amplification (median, 8.6) was significantly higher than that of each other gene amplification (two-sided P < 0.0001 for each, Mann–Whitney U-test). The boxes represent 25th–75th percentiles; center lines indicate the median; whiskers extend to the maximum and minimum values within 1.5× of the interquartile range; and dots indicate outliers. b, ctDNA fraction of patients with tissue+ctDNA+ (n = 32), tissue+ctDNA− (n = 7) and tissue−ctDNA+ (n = 6) for HER2 amplification. The ctDNA fraction of those with tissue+ctDNA− (median, 0.5%) was significantly lower than that with tissue+ctDNA+ (two-sided P = 0.011, Mann–Whitney U-test) or tissue−ctDNA+ (two-sided P = 0.035, Mann–Whitney U-test). The boxes represent 25th–75th percentiles; center lines indicate the median; whiskers extend to the maximum and minimum values within 1.5× of the interquartile range; and dots indicate outliers. c, Waterfall plot showing the change in the sum of the longest diameters of lesions from the baseline to the best post-baseline investigator assessment. Allocation to tissue+ or ctDNA+ group is shown by the boxes at the bottom of the figure. d, ORR in tissue+ (n = 27), ctDNA+ (n = 25) and SCRUM-Japan Registry (n = 13) patients. Error bars represent 95% CIs. e, Kaplan–Meier plots of PFS in the tissue+ group. Vertical lines denote patients who were censored. f, Kaplan–Meier plots of PFS in the tissue+ group.
Fig. 1 Clinical efficacy of pertuzumab plus trastuzumab for HER2-amplified mCRC. a, pCN of the ten most frequent gene amplifications in 1,107 patients with mCRC enrolled in GOZILA between January 2018 and March 2020. The pCN of HER2 amplification (median, 8.6) was significantly higher than that of each other gene amplification (two-sided P < 0.0001 for each, Mann–Whitney U-test). The boxes represent 25th–75th percentiles; center lines indicate the median; whiskers extend to the maximum and minimum values within 1.5× of the interquartile range; and dots indicate outliers. b, ctDNA fraction of patients with tissue+ctDNA+ (n = 32), tissue+ctDNA− (n = 7) and tissue−ctDNA+ (n = 6) for HER2 amplification. The ctDNA fraction of those with tissue+ctDNA− (median, 0.5%) was significantly lower than that with tissue+ctDNA+ (two-sided P = 0.011, Mann–Whitney U-test) or tissue−ctDNA+ (two-sided P = 0.035, Mann–Whitney U-test). The boxes represent 25th–75th percentiles; center lines indicate the median; whiskers extend to the maximum and minimum values within 1.5× of the interquartile range; and dots indicate outliers. c, Waterfall plot showing the change in the sum of the longest diameters of lesions from the baseline to the best post-baseline investigator assessment. Allocation to tissue+ or ctDNA+ group is shown by the boxes at the bottom of the figure. d, ORR in tissue+ (n = 27), ctDNA+ (n = 25) and SCRUM-Japan Registry (n = 13) patients. Error bars represent 95% CIs. e, Kaplan–Meier plots of PFS in the tissue+ group. Vertical lines denote patients who were censored. f, Kaplan–Meier plots of PFS in the tissue+ group.CC BY · PubMed Central
Fig. 2 Baseline, on-treatment and on-progression biomarker analysis for treatment with pertuzumab plus trastuzumab. a, Baseline alterations of known drivers by tissue or ctDNA genotyping. Patients are listed from left to right in order of increasing change in the sum of the longest diameters of lesions from the baseline to the best post-baseline investigator assessment. b, Receiver operating characteristics to predict the clinical benefit by pertuzumab plus trastuzumab using baseline HER2 status: FISH HER2/CEP17 ratio, FISH HER2 CN, tissue NGS copy number (tCN), pCN and ApCN. c, Kaplan–Meier plots of PFS for patients with tumors harboring tissue-based favorable factors (tissue CN ≥ 68.7 and no concurrent RTK/RAS/PI3K alterations) versus those lacking favorable factors. d, Kaplan–Meier plots of PFS for patients with tumors harboring ctDNA-based favorable factors (ApCN ≥ 16.7 and no concurrent RTK/RAS/PI3K alterations) versus those lacking favorable factors. e, Proportional change in ctDNA fraction by tumor response: complete response (CR) (n = 1), partial response (PR) (n = 7), stable disease (SD) with tumor shrinkage (n = 6), SD without tumor shrinkage (n = 3) and progressive disease (PD) (n = 8). f, Kaplan–Meier plots of PFS for patients with decreased versus increased ctDNA fraction. g, Acquired alterations at disease progression. NR, not reached.
Fig. 2 Baseline, on-treatment and on-progression biomarker analysis for treatment with pertuzumab plus trastuzumab. a, Baseline alterations of known drivers by tissue or ctDNA genotyping. Patients are listed from left to right in order of increasing change in the sum of the longest diameters of lesions from the baseline to the best post-baseline investigator assessment. b, Receiver operating characteristics to predict the clinical benefit by pertuzumab plus trastuzumab using baseline HER2 status: FISH HER2/CEP17 ratio, FISH HER2 CN, tissue NGS copy number (tCN), pCN and ApCN. c, Kaplan–Meier plots of PFS for patients with tumors harboring tissue-based favorable factors (tissue CN ≥ 68.7 and no concurrent RTK/RAS/PI3K alterations) versus those lacking favorable factors. d, Kaplan–Meier plots of PFS for patients with tumors harboring ctDNA-based favorable factors (ApCN ≥ 16.7 and no concurrent RTK/RAS/PI3K alterations) versus those lacking favorable factors. e, Proportional change in ctDNA fraction by tumor response: complete response (CR) (n = 1), partial response (PR) (n = 7), stable disease (SD) with tumor shrinkage (n = 6), SD without tumor shrinkage (n = 3) and progressive disease (PD) (n = 8). f, Kaplan–Meier plots of PFS for patients with decreased versus increased ctDNA fraction. g, Acquired alterations at disease progression. NR, not reached.CC BY · PubMed Central
Extended Data Fig. 1 HER2 amplification between tissue and ctDNA. In 75 patients tested by both HER2-Screening and GOZIA studies, the positive percent agreemen, negative percent agreement, and the overall agreement for HER2 amplification between tissue and ctDNA analysis was 82%, 83%, and 83%, respectively.
Extended Data Fig. 1 HER2 amplification between tissue and ctDNA. In 75 patients tested by both HER2-Screening and GOZIA studies, the positive percent agreemen, negative percent agreement, and the overall agreement for HER2 amplification between tissue and ctDNA analysis was 82%, 83%, and 83%, respectively.CC BY · PubMed Central
Extended Data Fig. 2 Baseline characteristics of patients receiving screening studies by tissue and ctDNA HER2 status. Data are n (%) or median (range). Tissue+ctDNA− patients more commonly received prior colorectal resection (two-sided P = 0.036, Fisher’s exact test) and had higher number of metastatic organs (two-sided P = 0.040, Mann-Whitney U test) than tissue+ctDNA− patients. ctDNA, circulating tumor DNA.
Extended Data Fig. 2 Baseline characteristics of patients receiving screening studies by tissue and ctDNA HER2 status. Data are n (%) or median (range). Tissue+ctDNA− patients more commonly received prior colorectal resection (two-sided P = 0.036, Fisher’s exact test) and had higher number of metastatic organs (two-sided P = 0.040, Mann-Whitney U test) than tissue+ctDNA− patients. ctDNA, circulating tumor DNA.CC BY · PubMed Central
Extended Data Fig. 3 Screening and enrollment. Tissue and ctDNA screening were separately conducted for patients with metastatic colorectal cancer. Patients with HER2 amplification confirmed by either of the screening studies were enrolled in the TRIUMPH study. Patients who were not enrolled in the TRIUMPH due to any reason, such as out of enrollment period, or who are at the site not participating in TRIUMPH were enrolled in the SCRUM-Japan Registry.
Extended Data Fig. 3 Screening and enrollment. Tissue and ctDNA screening were separately conducted for patients with metastatic colorectal cancer. Patients with HER2 amplification confirmed by either of the screening studies were enrolled in the TRIUMPH study. Patients who were not enrolled in the TRIUMPH due to any reason, such as out of enrollment period, or who are at the site not participating in TRIUMPH were enrolled in the SCRUM-Japan Registry.CC BY · PubMed Central
Extended Data Fig. 4 Baseline characteristics of patients in the TRIUMPH and SCRUM-Japan Registry. Summary of baseline characteristics of patients in the TRIUMPH and SCRUM-Japan Registry. Data are n (%) or median (range). Right-sided colon cancer was defined as cancer that is located in the cecum, ascending colon, or transverse colon, and left-sided colorectum cancer was defined as cancer that is in the descending colon, sigmoid colon, rectosigmoid colon, or rectum. ctDNA, circulating tumor DNA; ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
Extended Data Fig. 4 Baseline characteristics of patients in the TRIUMPH and SCRUM-Japan Registry. Summary of baseline characteristics of patients in the TRIUMPH and SCRUM-Japan Registry. Data are n (%) or median (range). Right-sided colon cancer was defined as cancer that is located in the cecum, ascending colon, or transverse colon, and left-sided colorectum cancer was defined as cancer that is in the descending colon, sigmoid colon, rectosigmoid colon, or rectum. ctDNA, circulating tumor DNA; ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.CC BY · PubMed Central
Extended Data Fig. 5 Best confirmed response. Summary of best confirmed response by investigator assessment to pertuzumab plus trastuzumab and standard-of-care treatment in SCRUM-Japan Registry. Data are n (%) or median (range). Right-sided colon cancer was d Data are n (%) or n (%, 95% CI).
Extended Data Fig. 5 Best confirmed response. Summary of best confirmed response by investigator assessment to pertuzumab plus trastuzumab and standard-of-care treatment in SCRUM-Japan Registry. Data are n (%) or median (range). Right-sided colon cancer was d Data are n (%) or n (%, 95% CI).CC BY · PubMed Central
Extended Data Fig. 6 HER2 status and efficacy of pertuzumab plus trastuzumab in three patients with HER2 amplification in ctDNA alone. All patients received prior anti-EGFR therapy before plasma collection. No HER2 amplification was identified in immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), or next generation sequencing (NGS) tests. Some pathogenic alterations not found in tissue were identified by ctDNA genotyping. No clinical benefit was achieved. pCN, plasma copy number; ApCN, adjusted pCN; and PFS, progression-free survival.
Extended Data Fig. 6 HER2 status and efficacy of pertuzumab plus trastuzumab in three patients with HER2 amplification in ctDNA alone. All patients received prior anti-EGFR therapy before plasma collection. No HER2 amplification was identified in immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), or next generation sequencing (NGS) tests. Some pathogenic alterations not found in tissue were identified by ctDNA genotyping. No clinical benefit was achieved. pCN, plasma copy number; ApCN, adjusted pCN; and PFS, progression-free survival.CC BY · PubMed Central
Extended Data Fig. 7 Overall survival. (a) Kaplan-Meier plots of overall survival (OS) in tissue-positive group. Vertical lines denote censored patients. (b) Kaplan-Meier plots of overall survival (OS) in ctDNA-positive group.
Extended Data Fig. 7 Overall survival. (a) Kaplan-Meier plots of overall survival (OS) in tissue-positive group. Vertical lines denote censored patients. (b) Kaplan-Meier plots of overall survival (OS) in ctDNA-positive group.CC BY · PubMed Central
Extended Data Fig. 8 Receiver operating characteristics analysis of baseline HER2 status. Summary of receiver operating characteristics (ROC) analysis of baseline HER2 status to predict the clinical benefit by pertuzumab plus trastuzumab. Baseline HER2 status included fluorescence in situ hybridization (FISH) HER2/CEP17 ratio, FISH HER2 copy number (CN), tissue NGS copy number (tCN), plasma copy number (pCN), and adjusted pCN (ApCN). The two-sided P value tests the null hypothesis that the area under the ROC curve is 0.5. Adjustments were not made for multiple comparisons. Threshold is determined as the point of the ROC curve which is closest to the perfect (1,0) coordinate.
Extended Data Fig. 8 Receiver operating characteristics analysis of baseline HER2 status. Summary of receiver operating characteristics (ROC) analysis of baseline HER2 status to predict the clinical benefit by pertuzumab plus trastuzumab. Baseline HER2 status included fluorescence in situ hybridization (FISH) HER2/CEP17 ratio, FISH HER2 copy number (CN), tissue NGS copy number (tCN), plasma copy number (pCN), and adjusted pCN (ApCN). The two-sided P value tests the null hypothesis that the area under the ROC curve is 0.5. Adjustments were not made for multiple comparisons. Threshold is determined as the point of the ROC curve which is closest to the perfect (1,0) coordinate.CC BY · PubMed Central
Extended Data Fig. 9 Overall survival according to tissue or ctDNA-based stratification. (a) Kaplan-Meier plots of OS for patients with tumors harboring tissue-based favorable factors (tissue CN ≥68.7 and no concurrent RTK/RAS/PI3K alterations) versus those lacking favorable factors. (b) Kaplan-Meier plots of OS for patients with tumors harboring ctDNA-based favorable factors (ApCN ≥16.7 and no concurrent RTK/RAS/PI3K alterations) versus those lacking favorable factors.
Extended Data Fig. 9 Overall survival according to tissue or ctDNA-based stratification. (a) Kaplan-Meier plots of OS for patients with tumors harboring tissue-based favorable factors (tissue CN ≥68.7 and no concurrent RTK/RAS/PI3K alterations) versus those lacking favorable factors. (b) Kaplan-Meier plots of OS for patients with tumors harboring ctDNA-based favorable factors (ApCN ≥16.7 and no concurrent RTK/RAS/PI3K alterations) versus those lacking favorable factors.CC BY · PubMed Central
Extended Data Fig. 10 Survival outcomes by change in ctDNA fraction. (a) Kaplan-Meier plots of OS for patients with decreased versus increased ctDNA fraction. (b) Forest plots depicting the association between proportional change in ctDNA fraction and PFS. The dot and error bars represent the point estimate of hazard ratio and 95% confidence intervals, respectively. (c) Forest plots depicting the association between proportional change in ctDNA fraction and OS. The dot and error bars represent the point estimate of hazard ratio and 95% confidence intervals, respectively.
Extended Data Fig. 10 Survival outcomes by change in ctDNA fraction. (a) Kaplan-Meier plots of OS for patients with decreased versus increased ctDNA fraction. (b) Forest plots depicting the association between proportional change in ctDNA fraction and PFS. The dot and error bars represent the point estimate of hazard ratio and 95% confidence intervals, respectively. (c) Forest plots depicting the association between proportional change in ctDNA fraction and OS. The dot and error bars represent the point estimate of hazard ratio and 95% confidence intervals, respectively.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 231

Metadata

Authors
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., Sawada, K., Taniguchi, H., Fuse, N., Nomura, S., Fukui, M., Matsuda, S., Sakamoto, Y., Uchigata, H., Kitajima, K., Kuramoto, N., Asakawa, T., Olsen, S., Odegaard, J. I., Sato, A., Fujii, S., Ohtsu, A., & Yoshino, T.
Affiliations
  • National Cancer Center Hospital East (JP)
  • Hiroshima University Hospital (JP)
  • Osaka National Hospital (JP)
  • National Hospital Organization Kyushu Cancer Center (JP)
  • National Cancer Center Hospital (JP)
  • Hokkaido University Hospital (JP)
  • Aichi Cancer Center (JP)
  • Shikoku Cancer Center (JP)
  • Aichi Cancer Center Research Institute (JP)
  • Kushiro Rosai Hospital (JP)
  • Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
  • Guardant (United States) (US)
  • National Cancer Center Exploratory Oncology Research & Clinical Trial Center (JP)
Corresponding author
Yoshino, Takayuki
Venue
Nature Medicine
Published
2021-11
Volume
27
Issue
11
Pages
1899-1903
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3212458558
Cited by
231
References
20
Citations by year
2026: 31 · 2025: 49 · 2024: 55 · 2023: 56 · 2022: 39 · 2021: 1
FWCI
14.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • SCRUM-Japan Funds
  • Japan Agency for Medical Research and Development (19ck0106445h0002, 16lk0201054h0001, 16lk0201056s0001)
  • National Cancer Center Research and Development Fund
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
circulating tumor DNA, HER2 amplification, metastatic colorectal cancer, pertuzumab, trastuzumab, dual HER2 blockade, treatment response monitoring, HER2 copy number, oncogenic alterations, patient selection for clinical trials, objective response rate
MeSH terms
Trastuzumab, Circulating Tumor DNA, Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Prospective Studies, Colorectal Neoplasms, Gene Dosage, Erb-b2 Receptor Tyrosine Kinases, Translational Research, Biomedical, Genotyping Techniques, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. https://app.cochat.ai/papers/10.1038/s41591-021-01553-w
The paper
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., Sawada, K., Taniguchi, H., Fuse, N., Nomura, S., Fukui, M., Matsuda, S., Sakamoto, Y., Uchigata, H., Kitajima, K., . . . Yoshino, T. (2021). Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01553-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.